Skip to main content
. 2020 Jan 31;6:3. doi: 10.1038/s41523-020-0145-3

Fig. 1. Consort diagram showing sample sources and processing scheme for identification of markers.

Fig. 1

Primary TNBC cancer samples from the Discovery cohort (N = 110) (not given chemotherapy) were evaluated to identify DNA methylation markers high in recurring and low in nonrecurring cancers. Candidate markers were then tested in the IBCSG No Chemo Test cohort (not given chemotherapy) (N = 49). Also evaluated was the combined IBCSG and Institutional Chemo cohort (N = 120) obtained from patients who received chemotherapy. Cases that recurred after 5 years and controls with less than 5 years of follow-up were excluded (5-year censoring).